Clinical Performance of Laryseal Clear vs Ambu Aura40 Laryngeal Mask Airway for Preschool Children
ClinicalTrials.gov Studies
Summary
A clinical trial comparing the performance of Laryseal Clear and Ambu Aura40 laryngeal mask airways in preschool children undergoing surgical procedures has been registered on ClinicalTrials.gov. The study will evaluate both devices as supraglottic airway devices in pediatric anesthesia settings. NCT07553247 was registered on April 27, 2026, and the trial will assign participants to either the LarySeal clear Group or the Ambu Aura40 Group.
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document registers a new clinical trial on ClinicalTrials.gov (NCT07553247) evaluating the clinical performance of two supraglottic airway devices: Laryseal Clear and Ambu Aura40, in preschool children undergoing surgical procedures. The trial is listed as a comparison study with two intervention groups.
Affected parties include clinical investigators conducting pediatric airway management research, medical device manufacturers sponsoring clinical trials, and healthcare institutions performing pediatric anesthesia. The registration provides no compliance obligations or regulatory deadlines beyond standard clinical trial reporting requirements.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Clinical Performance of Laryseal Clear Versus Ambu Aura 40 Laryngeal Mask Airway for Preschool Children
N/A NCT07553247 Kind: NA Apr 27, 2026
Abstract
Preschool children have specific anatomical and physiological characteristics which necessitates careful selection of an appropriate airway management device. Supraglottic airway devices can be used in anticipated or unanticipated difficult airway providing continuous oxygenation and ventilation with less hemodynamic stress response and less postoperative complications. So alternative techniques such as SADs have gained prominence in pediatric anesthesia both as primary airway and as a conduit for endotracheal intubation. So this study will evaluate the clinical performance of Laryseal Clear and Ambu Aura40 laryngeal mask airway in preschool children undergoing surgical procedures.
Conditions: Supraglottic Airway Devices, Laryseal Clear Laryngeal Mask
Interventions: LarySeal clear Group, Ambu Aura40 Group
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.